2. Search Result
Search Result
Results for "

KLF5

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

2

Natural
Products

1

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19994
    ML264
    10+ Cited Publications

    		 KLF Cancer
    ML264 is an antitumor agent that potently and selectively inhibits Krüppel-like factor five (KLF5) expression.
    ML264
  • HY-136530
    SR18662

    		KLF Cancer
    SR18662 is a potent inhibitor of Krüppel-like factor five (KLF5) with an IC50 of 4.4 nM and an analogue of ML264 (HY-19994) with improved inhibitory potency against colorectal cancer cells. SR18662 can be used for the study of colorectal cancer .
    SR18662
  • HY-N1570
    Pterosin B

    		Salt-inducible Kinase (SIK) KLF Amyloid-β Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
    Pterosin B is an orally active indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces β-amyloid deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes [5].
    Pterosin B
  • HY-139691
    SR15006

    		KLF Cancer
    SR15006 is a inhibitor of Krüppel-like factor 5 (KLF5) with an IC50 of 41.6 nM in DLD-1/pGL4.18hKLF5p cells) .
    SR15006
  • HY-W011044
    CID 5951923
    1 Publications Verification

    		 KLF Cancer
    CID 5951923 is a potent inhibitor of Krüppel-like factor 5 (KLF5), with an IC50 of 603 nM. CID 5951923 can inhibit proliferation of cancer cells in vitro .
    CID 5951923
  • HY-RS07342
    KLF5 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    KLF5 Human Pre-designed siRNA Set A contains three designed siRNAs for KLF5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    KLF5 Human Pre-designed siRNA Set A
    KLF5 Human Pre-designed siRNA Set A
  • HY-RS23111
    Klf5 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Klf5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Klf5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Klf5 Rat Pre-designed siRNA Set A
    Klf5 Rat Pre-designed siRNA Set A
  • HY-RS16676
    Klf5 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Klf5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Klf5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Klf5 Mouse Pre-designed siRNA Set A
    Klf5 Mouse Pre-designed siRNA Set A
  • HY-169213
    LN-439A

    		KLF RAD51 Cancer
    LN-439A (compound LN-439A) is a BAP1 inhibitor that inhibits the growth of basal-like breast cancer by degrading KLF5. .
    LN-439A
  • HY-N1570R
    Pterosin B (Standard)

    		Reference Standards Salt-inducible Kinase (SIK) KLF Amyloid-β Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
    Pterosin B (Standard) is the analytical standard of Pterosin B (HY-N1570). This product is intended for research and analytical applications. Pterosin B is an indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces β-amyloid deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes [5].
    Pterosin B (Standard)
  • HY-162875
    PROTAC BRD4 Degrader-27

    		PROTACs Epigenetic Reader Domain Cancer
    PROTAC BRD4 Degrader-27 (compound 6b) is a PROTAC that selectively targets BRD4 (rather than BRD2/BRD3) and can also inhibit the expression of KLF5 transcription factor and exert anti-cancer activity. PROTAC BRD4 Degrader-27 is composed of E3 ubiquitinase ligand Thalidomide-4-OH (HY-103596) (red part), PROTAC Linker γ-Aminobutyric acid (HY-N0067) (black part) and PROTAC target protein ligand PROTAC BRD4 ligand-3 (HY-162876) (blue part), of which the active control of the target protein ligand is Mivebresib (HY-100015), and the conjugate of E3 ubiquitin ligase ligand + Linker is Pomalidomide 4'-alkylC3-acid (HY-131875) [1] .
    PROTAC BRD4 Degrader-27
  • HY-182820
    YZ-836P

    		Histone Methyltransferase PROTACs KLF Cancer
    YZ-836P is a Protein arginine methyltransferase 5 (PRMT5) targeting agent. YZ-836P promotes ubiquitination and proteasomal degradation of PRMT5 in a cereblon (CRBN)-dependent manner, which in turn reduces levels of its downstream target KLF5. YZ-836P induces G1 phase cell cycle arrest in triple-negative breast cancer cells. YZ-836P induces Apoptosis in triple-negative breast cancer cells. YZ-836P exerts cytotoxic effects on triple-negative breast cancer cells. YZ-836P inhibits the growth of triple-negative breast cancer patient-derived organoids. YZ-836P inhibits the growth of triple-negative breast cancer xenografts in nude mice. YZ-836P can be used for the research of triple-negative breast cancer .
    YZ-836P

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: